In an analysis of more than 6,800 colon cancer patients across all University of California Health sites, researchers found that those taking glucagon-like peptide-1 (GLP-1) medications were less than half as likely to die within five years compared to those who werent on the drugs (15.5% vs
10.1080/00365520410010634 46 RebosioC.BalbiM.PassalacquaM.RicciarelliR.FedeleE
This is consistent with our observations reported in this paper
Glowing skin isnt just about makeup or surface careits about giving your skin the right ingredients that work from within
What are the indications, dosing regimen, contraindications, and monitoring recommendations for initiating GLP1 receptor agonist therapy in adults with type 2 diabetes?
Ascidian chief scientific officer Robert Bell (L) overlooks research in the company's lab in Boston (courtesy Ascidian) Lilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseases Last month, Ascidian Therapeutics presented the first data suggesting a new way to fix broken genes may be safe in people